Latest Commercialisation News

Volt Group reported a 15% decline in Q2 FY25 revenue due to customer order timing delays but secured new Wescone orders pointing to a strong Q3 recovery. Meanwhile, EcoQuip and ATEN projects advanced with promising demonstrations and feasibility studies.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Carnegie Clean Energy has made significant strides in advancing its wave energy technologies, signing key MOUs and achieving critical milestones in the ACHIEVE Programme during the June 2025 quarter.

Acrux Limited has secured a decade-long licensing agreement with Servacure to commercialise its FDA-approved Dapsone 5% Gel in Saudi Arabia, marking a strategic step in its global expansion.

Lithium Universe Limited has secured global rights to a breakthrough solar panel recycling technology that promises to unlock vast reserves of critical minerals, while advancing its Québec lithium refinery with robust financials and strategic partnerships.

Nyrada reports successful completion of five cohorts in its Phase I trial of Xolatryp with no safety concerns, alongside compelling preclinical neuro- and cardioprotective data. A Phase IIa trial targeting heart attack patients is slated for early 2026.

EV Resources has secured a 70% stake in the Los Lirios Antimony Project, unveiling high-grade mineralisation and plans for a pilot plant to accelerate production. Leadership enhancements and portfolio rationalisation underscore its strategic pivot to critical minerals.

Galan Lithium has locked in a $20 million strategic placement and secured a key Argentine government incentive, positioning its Hombre Muerto West project for production in early 2026.

Strategic Elements Ltd has marked significant progress in its Energy Ink™ prototype trials and underground mining technology, maintaining a robust financial footing with $4.21 million cash and no debt.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.

First Graphene Limited reports over A$1.2 million in annual income, driven by new commercial orders and breakthrough graphene applications in mining safety boots and cement additives.

Bio-Gene Technology Limited has secured $2.45 million to fund critical safety studies and scale-up production of its novel insecticides Flavocide and Qcide, positioning the company for upcoming regulatory approvals and commercial partnerships.